Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propranolol + gabapentin
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and gabapentin (an anticonvulsant medication). This combination is primarily used for treating essential tremor and has shown potential benefit in managing paroxysmal sympathetic hyperactivity (PSH). While each drug has established individual uses, their combination may have synergistic effects that require careful dosing management.
- Other names
- propranolol and gabapentin
02
Targets
α2δ (Voltage-gated calcium channel alpha-2-delta subunit)ADRB1 (β1)ADRB2 (β2)ADRB3 (β3)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on propranolol + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propranolol + gabapentin.